

IN THE CLAIMS

Claim 1(original): Use of ubiquinones for preparing a medicament for reducing histamine activity in diseases selected from bronchitis, pneumonia, allergic asthma, multiple chemical sensitivity, hay fever, hypersensitivity reactions of the immediate type (type 1), endotoxin shock, histamine release induced by pharmaceuticals, skin diseases, renal insufficiency and burns.

Claim 2(original): The use according to claim 1, characterized in that said pharmaceutical-induced histamine release is caused by D-tubocurarin, suxamethonium, opiates, X-ray contrast agents, narcotics and/or chloroquine.

Claim 3(currently amended): The use according to claim 1 ~~at least one of claims 1 to 2~~, characterized in that ubiquinone is in the form of nanoparticles having a size of from 10 to 1000 nm.

Claim 4(currently amended): The use according to claim 1 ~~at least one of claims 1 to 3~~, characterized in that said medicament is in a form adapted for oral, inhalatory, intravenous, intraarterial, subcutaneous, intracutaneous, intramuscular or topical application.

Claim 5(original): Use of ubiquinones for influencing the activity of histamines and other mediators.

Claim 6(original): The use according to claim 5, characterized in that said mediators are selected from the group consisting of PAF and leukotrienes.

Claim 7(currently amended): The use according to claim 5 ~~or 6~~, characterized in that ubiquinones are used for influencing bronchoconstriction of the lung, pulmonary vascular resistance, elasticity of the lung, bowel contractions, epithelial constriction, vascular contractions, for reducing catecholamine release from the adrenal medulla and/or histamine-caused itching or pain at nerve ends, excessive secretion of gastric juice, tachycardia and/or the positive-ionotropic effect on the heart.

Claim 8(currently amended): The use according to claim 5 ~~at least one of claims 5 to 7~~, characterized in that said ubiquinone is in the form of nanoparticles having a size of from 10 to 1000 nm.

Claim 9(currently amended): The use according to claim 1 ~~at least one of claims 1 to 8~~, characterized in that said ubiquinone ~~ubidacarenone~~ is 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone.

Claim 10(original): Use of ubiquinones for preparing a food supplement or cosmetic preparation for reducing histamine activity.